Metraipolis › archive › dc_f37ab85eb05f

Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy — Europe PMC PMID:41976293

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41976293
DOI
10.3390/cancers18071070
License (as archived)
solo-consultazione
Archived
2026-11-03T21:37:41.867Z
SHA-256 of the archived text
bacd4fbe1269de44586743ff14c8bc8da72b8446f0d1977ed4aaf03a6c2d3599
Stable URL of this page
https://metraipolis.com/documento/dc_f37ab85eb05f

How to cite

Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy — Europe PMC PMID:41976293 — Europe PMC (en), https://europepmc.org/article/MED/41976293 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f37ab85eb05f (Metraipolis archive dc_f37ab85eb05f, sha256 bacd4fbe1269de44586743ff14c8bc8da72b8446f0d1977ed4aaf03a6c2d3599)
BibTeX
@misc{dcf37ab85eb05f,
  title = {Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy — Europe PMC PMID:41976293},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41976293},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f37ab85eb05f; sha256 bacd4fbe1269de44586743ff14c8bc8da72b8446f0d1977ed4aaf03a6c2d3599},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41976293. Agents can read the archived copy with the MCP tool read_document.